6 recalls found for Zydus Pharmaceuticals. Check if any of your products are affected.
Zydus Pharmaceuticals recalled 22,896 bottles of Icosapent Ethyl capsules on December 30, 2025. The recall stems from leakage and oxidation that may reduce the drug's effectiveness. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
The FDA confirms a nationwide recall of Zydus Lifesciences Chlorpromazine Hydrochloride tablets 200 mg (NDC 70710-1133-1) distributed by Zydus Pharmaceuticals USA. The recall cites CGMP deviations and the presence of N-Nitroso Desmethyl Chlorpromazine above acceptable intake. Consumers and healthcare providers should stop using the product immediately and contact the distributor for guidance.
Zydus Lifesciences and Zydus Pharmaceuticals US recall Chlorpromazine Hydrochloride Tablets, 10 mg, 100-count bottles sold nationwide in the United States after detecting an impurity above acceptable intake. The impurity is N-Nitroso Desmethyl Chlorpromazine. Consumers should stop using the product immediately and contact the manufacturer for guidance.
Zydus Lifesciences Ltd. recalled Chlorpromazine Hydrochloride tablets, 25 mg, 100-count bottles distributed nationwide by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. The recall cites CGMP deviations and the presence of N-Nitroso Desmethyl Chlorpromazine above the acceptable intake limit. Stop using the product and contact your healthcare provider or Zydus Pharmaceuticals (USA) Inc. for
Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc. recall Chlorpromazine Hydrochloride Tablets, USP, 100 mg, 100-count bottles distributed nationwide in the United States. The recall stems from CGMP deviations that allowed N-Nitroso Desmethyl Chlorpromazine to exceed the acceptable intake limit. Health care providers and patients should stop using the product and contact the manufacturer